Pacemaker Implantation in Neonates and Infants: Favorable Outcomes with Epicardial Pacing Systems.
Marc WildbolzHitendu DaveRoland WeberMatthias GassChristian BalmerPublished in: Pediatric cardiology (2020)
The implantation of pacemakers (PM) in neonates and infants requires particular consideration of small body size, marked body growth potential, and the decades of future pacing therapy to be expected. The aim of this study is to quantify the complications of implantation and outcome occurring at our center and to compare these with other centers. Retrospective analysis of 52 consecutive patients undergoing PM implantation at a single tertiary care center within the first year of life. PMs were implanted at a median age of 3 months (range 0-10 months). Structural heart defects were present in 44 of 52 patients. During a median follow-up time of 40.4 months (range 0.1-114 months), measurements for sensing, pacing thresholds, and lead impedance remained stable. No adverse pacing effect was observed in left ventricular function or dimensions over time. There were 20 reoperations in 13 patients at a median time of 4.7 years (range 0.05-8.2 years) after implantation, for end of battery life (n = 10), lead dysfunction (n = 3), device dislocation (n = 3), infection (n = 3), and diaphragmatic paresis (n = 1). No PM-related mortality occurred. Epicardial pacemaker implantation in neonates and infants is an invasive but safe and effective procedure with a relatively low risk of complications. Our current implantation technique and the use of bipolar steroid-eluting electrodes, which we prefer to implant on the left ventricular apex, lead to favorable long-term results.
Keyphrases
- left ventricular
- cardiac resynchronization therapy
- heart failure
- patients undergoing
- air pollution
- ejection fraction
- tertiary care
- risk factors
- heavy metals
- chronic kidney disease
- cardiovascular disease
- stem cells
- end stage renal disease
- polycyclic aromatic hydrocarbons
- aortic stenosis
- type diabetes
- risk assessment
- hypertrophic cardiomyopathy
- oxidative stress
- metabolic syndrome
- atrial fibrillation
- coronary artery disease
- computed tomography
- mesenchymal stem cells
- cross sectional
- magnetic resonance
- vena cava
- bone marrow
- adipose tissue
- acute coronary syndrome
- climate change
- gold nanoparticles
- left atrial
- percutaneous coronary intervention
- carbon nanotubes
- inferior vena cava
- replacement therapy
- drug induced
- catheter ablation